Event Calendar
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
WIDERA Info Day 2023-2024 calls
This was 1 year ago
LocationVirtual
ProgrammesThis info day organized by the European Commission aims to inform (potential) applicants about the new topics included in the Widening participation and strengthening the European Research Area (WIDERA) work programme of 2023-2024.
Horizon Europe’s Widening actions support EU countries that lag behind in research and innovation to increase their performance, while ERA actions aim at reforming and enhancing the European research and innovation system overall.
The morning session will focus on the widening part and the afternoon session on the ERA part.
Recording Widening part and ERA part
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Event calendar
36 upcoming events view event calendarHealth Climate, Energy, Mobility Agro-Food, Environment Missions
EU Missions Info Day 2024 calls
Testimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
